Delivery Order SPE2DR25D1100-SPE2DR26FCS1T
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) at a ceiling value of $2,378.33. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on August 29, 2025, with performance to be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of Gemtesa 75 mg tablets (90-count) with a ceiling value of $7,352.71. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract was awarded competitively with no set-aside designation....
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $4,299.80 on November 12, 2025, for the supply of Gemtesa 75 mg tablets (90-count packaging), with an ultimate completion date of November 13, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) valued at $14,184.24 on November 10, 2025, with completion scheduled for November 12, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $8,938.51 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of September 12, 2025. The award will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $27,132.48 delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Gemtesa 75 mg tablets (90-count packages). This firm fixed-price, non-set-aside contract is scheduled for completion by December 3, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader indefinite delivery contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,376.00 to supply Gemtesa 75 mg tablets (90-count packaging) with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Gemtesa 75 mg tablets (90-count packages) with a ceiling value of $40,767.56. This firm fixed-price delivery order, which must be completed by June 9, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The award was competitively procured with no set-aside designation and will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 25, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $8,353.48. This firm fixed-price delivery order, with an ultimate completion date of November 26, 2025, represents a non-set-aside, competitively awarded contract. The pharmaceutical product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $45.5K delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCS1TDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on December 1, 2025, for Gemtesa 75 mg tablets (90-count), valued at $6,002.46 under a firm fixed-price contract type with no set-aside designation. The order is due for completion by December 2, 2025, and will be fulfilled from the contractor's Conshohocken, Pennsylvania location. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), an approximately $1 billion vehicle running through December 2026 that provides comprehensive global pharmaceutical support for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal healthcare vendor that supplies an extensive portfolio of medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems. The company has demonstrated consistent capability to meet federal procurement requirements through competitive awards across multiple therapeutic domains. This specific delivery order for Gemtesa, a medication used in the treatment of overactive bladder, reflects the contractor's role in supplying essential pharmaceutical products through the DLA's medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 11/30/25 |